iBio, Inc. (IBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
IBIO Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for IBIO is 0.04 -- better than only 10.03% of US stocks.
- With a price/sales ratio of 24.82, IBIO INC has a higher such ratio than 94.89% of stocks in our set.
- Revenue growth over the past 12 months for IBIO INC comes in at -6.23%, a number that bests only 15.96% of the US stocks we're tracking.
- Stocks that are quantitatively similar to IBIO, based on their financial statements, market capitalization, and price volatility, are SCWX, CTSO, ATEN, VTEX, and DIOD.
- Visit IBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.ibioinc.com.
IBIO Valuation Summary
- In comparison to the median Healthcare stock, IBIO's price/earnings ratio is 111.73% lower, now standing at -2.3.
- IBIO's EV/EBIT ratio has moved up 6.4 over the prior 156 months.
Below are key valuation metrics over time for IBIO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| IBIO | 2022-09-23 | 26.7 | 0.9 | -2.3 | -2.0 |
| IBIO | 2022-09-22 | 28.7 | 1.0 | -2.4 | -2.2 |
| IBIO | 2022-09-21 | 29.5 | 1.0 | -2.5 | -2.3 |
| IBIO | 2022-09-20 | 26.4 | 0.9 | -2.2 | -2.0 |
| IBIO | 2022-09-19 | 29.5 | 1.0 | -2.5 | -2.3 |
| IBIO | 2022-09-16 | 35.7 | 1.3 | -3.0 | -2.8 |
IBIO Growth Metrics
- Its year over year net income to common stockholders growth rate is now at -22.73%.
- Its 2 year net cashflow from operations growth rate is now at -139.39%.
- The 2 year cash and equivalents growth rate now stands at 295.5%.
The table below shows IBIO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-03-31 | 2.813 | -33.203 | -33.286 |
| 2021-12-31 | 1.635 | -34.608 | -28.621 |
| 2021-09-30 | 2.172 | -32.341 | -24.873 |
| 2021-06-30 | 2.371 | -30.064 | -23.467 |
| 2021-03-31 | 3 | -26.705 | -27.121 |
| 2020-12-31 | 2.331 | -23.142 | -24.137 |
IBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IBIO has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
- IBIO's asset turnover comes in at 0.017 -- ranking 375th of 681 Pharmaceutical Products stocks.
- COLL, COCP, and IRWD are the stocks whose asset turnover ratios are most correlated with IBIO.
The table below shows IBIO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.017 | 0.383 | -0.256 |
| 2021-03-31 | 0.024 | 0.836 | -0.331 |
| 2020-12-31 | 0.023 | 1.000 | -0.317 |
| 2020-09-30 | 0.027 | 1.000 | -0.273 |
| 2020-06-30 | 0.032 | 1.000 | -0.231 |
| 2020-03-31 | 0.036 | 1.000 | -0.271 |
IBIO Stock Price Chart Interactive Chart >
IBIO Price/Volume Stats
| Current price | $0.17 | 52-week high | $1.07 |
| Prev. close | $0.18 | 52-week low | $0.17 |
| Day low | $0.17 | Volume | 3,564,636 |
| Day high | $0.19 | Avg. volume | 2,403,633 |
| 50-day MA | $0.28 | Dividend yield | N/A |
| 200-day MA | $0.35 | Market Cap | 37.15M |
iBio, Inc. (IBIO) Company Bio
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.
Latest IBIO News From Around the Web
Below are the latest news stories about IBIO INC that investors may wish to consider to help them evaluate IBIO as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning. |
Edited Transcript of IBIO.A earnings conference call or presentation 27-Sep-22 8:30pm GMTQ4 2022 Ibio Inc Earnings Call |
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate UpdateBRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. “We have continued to take important steps toward achieving our strategic objective of becoming a leading biotechnology company with a focu |
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline– Positions Company for leadership in AI-powered drug discovery – – Expands iBio’s immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company’s transformation and FY2022 financial results – SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today a |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news behind them! |
IBIO Price Returns
| 1-mo | -38.69% |
| 3-mo | -34.62% |
| 6-mo | -60.66% |
| 1-year | -83.96% |
| 3-year | -68.38% |
| 5-year | -94.69% |
| YTD | -69.03% |
| 2021 | -47.71% |
| 2020 | 321.69% |
| 2019 | -66.80% |
| 2018 | -57.63% |
| 2017 | -55.75% |
Continue Researching IBIO
Want to do more research on iBio Inc's stock and its price? Try the links below:iBio Inc (IBIO) Stock Price | Nasdaq
iBio Inc (IBIO) Stock Quote, History and News - Yahoo Finance
iBio Inc (IBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...